FLT3 and acute myeloid leukemia: FLT3/ITDs was detected in 37% of our AML patients, this frequency was close to that previously reported by (Gorin et al., 2013; Farawela et al., 2014; Kassem et al., 2019) where the frequency of FLT3/ITDs ranged between 15.4–36% among their AML patients.